<
AI
Automation
Science
Innovation
Open Source
Blockchain
Social Media
Startups
Culture
Cloud
>

qz
Lilly (LLY) Surges 3.8%: Is This an Indication of Further Gains?

Lilly (LLY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue mo [...]

Discover Copy
Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination
Eli Lilly's online health platform just expanded beyond weight loss to tackle Alzheimer’s

Just about a year after launching a direct-to-consumer online platform to sell treatments for diabetes and obesity, Eli Lilly (LLY) is now expanding the program to offer resources for Alzheimer’s d [...]

Match Score: 63.03

Destination
Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — and Eli Lilly’s drug came out on top.Read more... [...]

Match Score: 63.03

Destination
Eli Lilly CEO David Rick’s’ pay rose to nearly $30 million in 2024

Eli Lilly (LLY) CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the most valuable pharmaceutical company in the world.Read more.. [...]

Match Score: 55.12

Destination
Eli Lilly's first weight-loss pill could expand access to GLP-1s around the globe, executive says

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.Read more... [...]

Match Score: 55.12

Destination
Eli Lilly's Alzheimer's drug is rejected by EU regulators over brain swelling risk, despite U.S. approval

The European Union’s health regulator on Friday rejected Eli Lilly’s (LLY) Alzheimer’s drug, Kisunla, citing risks of brain swelling and bleeding. It’s a major setback for the company as it co [...]

Match Score: 55.12

Destination
Eli Lilly and Novo Nordisk are tackling heart health next

After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart health.Read more... [...]

Match Score: 55.12

Destination
Eli Lilly is coming after makers of copycat versions of Zepbound

Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs, Mounjaro and Zepbound.Read more... [...]

Match Score: 55.12

Destination
Eli Lilly promises to make new weight-loss pill in the U.S.

Eli Lilly (LLY) CEO Dave Ricks said Friday that the company will make its planned GLP-1 weight-loss pill in the U.S. amid President Donald Trump’s sweeping tariffs and his push to get companies to [...]

Match Score: 55.12

Destination
Eli Lilly is stepping up its fight against copycat weight-loss drugs

In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth companies that offer cheaper versions of its blockbuster GLP-1 weight loss dr [...]

Match Score: 55.12